Squarepoint Ops LLC Buys Shares of 32,060 SI-BONE, Inc. (NASDAQ:SIBN)

Squarepoint Ops LLC purchased a new position in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 32,060 shares of the company's stock, valued at approximately $449,000. Squarepoint Ops LLC owned about 0.08% of SI-BONE at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SIBN. American Century Companies Inc. boosted its holdings in shares of SI-BONE by 11.0% during the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after acquiring an additional 236,167 shares during the period. Silvercrest Asset Management Group LLC lifted its position in SI-BONE by 21.9% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock valued at $27,392,000 after purchasing an additional 350,970 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in SI-BONE by 17.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,263,988 shares of the company's stock valued at $17,721,000 after purchasing an additional 190,830 shares during the period. Geode Capital Management LLC grew its position in SI-BONE by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 933,891 shares of the company's stock worth $13,097,000 after purchasing an additional 9,847 shares during the last quarter. Finally, Impax Asset Management Group plc grew its position in SI-BONE by 1.1% in the 4th quarter. Impax Asset Management Group plc now owns 766,761 shares of the company's stock worth $10,750,000 after purchasing an additional 8,240 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.

Wall Street Analyst Weigh In

SIBN has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a report on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and issued a $24.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Truist Financial lifted their target price on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th.

Insider Buying and Selling at SI-BONE

In related news, insider Anthony J. Recupero sold 3,311 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the completion of the sale, the insider now directly owns 284,555 shares in the company, valued at approximately $4,026,453.25. This trade represents a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Pisetsky sold 3,128 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the transaction, the senior vice president now directly owns 244,878 shares in the company, valued at $3,462,574.92. The trade was a 1.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 95,942 shares of company stock valued at $1,734,203 in the last three months. 4.00% of the stock is currently owned by company insiders.

SI-BONE Price Performance

Shares of NASDAQ SIBN traded down $0.16 during mid-day trading on Friday, reaching $18.90. The company had a trading volume of 485,058 shares, compared to its average volume of 383,448. The company has a 50-day moving average price of $16.10 and a two-hundred day moving average price of $15.56. The stock has a market cap of $805.42 million, a PE ratio of -20.54 and a beta of 0.94. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $20.05.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.09. The business had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. On average, equities analysts anticipate that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.